公开(公告)号：US20240398736A1

公开(公告)日：2024-12-05

申请号：US18266103

申请日：2021-09-01

Applicant: Tsubota Laboratory, Inc. ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuo Tsubota ,  Toshihide Kurihara ,  Shinichi Ikeda ,  Kiwako Mori ,  Xiaoyan Jiang

IPC: A61K31/192 ,  A61P27/10 ,  G01N33/50

Abstract: The present invention provides a screening method for searching a component inhibiting or treating scleral thinning, and eyedrops that contain the active ingredient, and hence can inhibit excessive thinning of the sclera, and as a result, can treat a posterior segment eye disease associated with the scleral thinning. The problems are solved by eyedrops containing, as an active ingredient, a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway. The problems are solved by a screening method for a component capable of simultaneously inhibiting the PERK pathway and/or the ATF6 pathway, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an indicator, influence on scleral thinning in the cell.

公开(公告)号：US20230285562A1

公开(公告)日：2023-09-14

申请号：US18018105

申请日：2021-07-30

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Ozora Kubo ,  Saeko Hayashi ,  Akiko Kita

IPC: A61K47/02 ,  A61K9/00 ,  A61K9/08 ,  A61K31/519 ,  A61K47/12

CPC classification number: A61K47/02 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/519 ,  A61K47/12

Abstract: The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of citric acid, phosphoric acid, and a salt thereof (B).

公开(公告)号：US20230277595A1

公开(公告)日：2023-09-07

申请号：US18016978

申请日：2022-02-09

Applicant: ROHTO PHARMACEUTICAL CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Shunbun KITA ,  Emi HORITANI ,  Norikazu MAEDA ,  Iichiro SHIMOMURA ,  Hiroyuki NISHIDA

IPC: A61K35/28 ,  A61P3/10

CPC classification number: A61K35/28 ,  A61P3/10

Abstract: The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.

公开(公告)号：US20230172969A1

公开(公告)日：2023-06-08

申请号：US17921065

申请日：2021-03-31

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Tatsuya Ando ,  Yoko Mitsuguchi ,  Sachiko Matsumoto ,  Atsuko Nakata

IPC: A61K31/737 ,  A61K9/00 ,  A61K31/23 ,  A61K31/355 ,  A61K31/205 ,  A61K31/198 ,  A61K31/27 ,  A61K47/38 ,  A61K31/4415 ,  A61K31/16 ,  A61P27/04 ,  A61K31/4166 ,  A61K31/704

CPC classification number: A61K31/737 ,  A61K9/0048 ,  A61K31/23 ,  A61K31/355 ,  A61K31/205 ,  A61K31/198 ,  A61K31/27 ,  A61K47/38 ,  A61K31/4415 ,  A61K31/16 ,  A61P27/04 ,  A61K31/4166 ,  A61K31/704

Abstract: The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.

公开(公告)号：US20230094229A1

公开(公告)日：2023-03-30

申请号：US17770298

申请日：2019-10-21

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Hiroyuki Koshiro ,  Naohiro Ikeda

IPC: A61J1/06 ,  A61J1/14 ,  B65D1/09 ,  B32B27/08 ,  B32B27/32

Abstract: The present invention is a resin container having a multilayer structure including a first layer that comes into contact with liquid content and a second layer that is in contact with the first layer from an outer side of the first layer. The first layer includes a cyclic olefin copolymer and a linear low-density polyethylene resin, and the second layer includes a low-density polyethylene resin.

公开(公告)号：US20220280515A1

公开(公告)日：2022-09-08

申请号：US17632419

申请日：2020-08-06

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Yoshihiro Takai ,  Takahiro Kurose

IPC: A61K31/519 ,  A61P27/04

Abstract: The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.

公开(公告)号：US11167889B2

公开(公告)日：2021-11-09

申请号：US16603956

申请日：2018-04-13

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Naohiro Ikeda ,  Hiroyuki Koshiro

IPC: B65D35/08 ,  B65D47/20 ,  B65D1/02 ,  A61J1/05 ,  A61J1/14 ,  A61J1/06 ,  B65D1/09

Abstract: The present invention relates to a squeeze bottle integrally including a container body including a housing portion for housing a liquid composition and a spout connected to the housing portion; and a lid joined to the container body so as to seal an opening of the spout, in which the container body contains a resin containing cyclic olefins and polyethylenes.

公开(公告)号：US20210046122A1

公开(公告)日：2021-02-18

申请号：US16961354

申请日：2019-01-11

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kohji NISHIDA ,  Ryuhei HAYASHI ,  Shun SHIBATA ,  Toru OKUBO ,  Yoichi HONMA

IPC: A61K35/28 ,  A61P27/02

Abstract: The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation/maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

公开(公告)号：USD903861S1

公开(公告)日：2020-12-01

申请号：US29652059

申请日：2020-04-28

Applicant: Rohto Pharmaceutical Co., Ltd.

Designer： Chiyoko Otsu ,  Takashi Hamada

公开(公告)号：US20190151284A1

公开(公告)日：2019-05-23

申请号：US16313876

申请日：2017-06-28

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Masatoshi HAGA ,  Yuya HAYASHI

IPC: A61K31/375 ,  A61K9/00 ,  A61K47/10 ,  A61K47/18 ,  A61K47/24 ,  A61P17/10 ,  A61P17/18 ,  A61K8/67 ,  A61K8/86 ,  A61K8/34 ,  A61K8/55 ,  A61K8/41 ,  A61Q19/02 ,  A61Q19/08

Abstract: Provided is an external composition excellent in stability and impression from use. An external composition containing (A) at least one member selected from the group consisting of ascorbic acid and salts of ascorbic acid, (B) at least one member selected from the group consisting of 3-O-ethylascorbic acid, salts of 3-O-ethylascorbic acid, and hydroxylated lecithin, and (C) polyethylene glycol is prepared.